未來來展望

毛細管電泳法具有進樣量量少，分離離效率率率高，分離離時間短，及具自動化分析等優點。然而若若單純搭配紫外光偵測器，則毛細管電泳法的偵測極限往往過高，造成偵測不不到的情況。這也是本實驗中，在癌症或健康對照組皆偵測不不到 8-羥基去氧鳥苷與雙甲基鳥苷的原因。一般作法是增加一個萃取的步驟，在進樣至儀器前先進行行萃取，使分析物濃度度高於儀器的偵測極限，以增進分析的靈靈敏度度，同時可以去除基質干擾，而選擇更更靈靈敏的偵測器，如電化學偵測、雷雷射誘導螢光偵測或質譜儀。然而考量量到癌症生物標記篩檢所需要的快速大量量分析能力力與經濟性，

吾人初步將朝向線上濃縮方向發展，使用大樣品體積堆積（Large-Volum Sample Stacking，LVSS）、樣品掃集法 (sweeping) 或 pH 值界面堆積 (Dynamic pH junction stacking) 等方法，進一步提昇偵測的靈靈敏度度。

單一種核苷的正常值還未有定論論，且無法直接用於診斷單一種癌症，然而數數種尿尿中核苷的濃度度所組成代謝體學，與癌症疾病的關係是一個很有潛力力的研究方向。此外尿尿中核苷的角色也不不僅止於輔助診斷，還可應用於疾病治療療效果的評估，

如 Sung-Hee Cho 等人檢測了了乳癌病人手術前後尿尿中核苷的變化 [28]，認為這種目標性的代謝體學，能應用於監測治療療效果。因此吾人未來來研究方向也包括增加偵測尿尿液中核苷的數數目，以及收集癌症病患治療療前後的尿尿液檢體進行行分析，期望能發現有助於臨臨床應用的癌症生物標記。

第六六章參參考文獻

1. Department of Health, the Executive Yuen. (2013). from

www.mohw.gov.tw/MOHW_Upload/doc/民國 101 年年主要死因分析.doc 2. Cornfield, J., Haenszel, W., Hammond, E. C., Lilienfeld, A. M., Shimkin, M.

B., & Wynder, E. L. (2009). Smoking and lung cancer: recent evidence and a discussion of some questions. International journal of epidemiology, 38(5), 1175-1191.

3. Hirayama, T. (2000). Non-smoking wives of heavy smokes have a higher risk of lung cancer: a study from Japan. Bulletin of the World Health Organization, 78(7), 940-942.

4. Michielsen, P. P., Francque, S. M., & van Dongen, J. L. (2005). Viral hepatitis and hepatocellular carcinoma. World journal of surgical oncology, 3(1), 27.

5. Bosch, F., Lorincz, A., Munoz, N., Meijer, C., & Shah, K. (2002). The causal relation between human papillomavirus and cervical cancer. Journal of clinical pathology, 55(4), 244-265.

6. Saslow, D., Runowicz, C. D., Solomon, D., Moscicki, A. B., Smith, R. A., Eyre, H. J., & Cohen, C. (2002). American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA: a cancer journal for clinicians, 52(6), 342-362.

7. Zauber, A. G., Winawer, S. J., O'Brien, M. J., Lansdorp-Vogelaar, I., van Ballegooijen, M., Hankey, B. F., . . . Panish, J. F. (2012). Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. New England Journal of Medicine, 366(8), 687-696.

8. Chen, T. H. H., Chen, C. J., Yen, M. F., Lu, S. N., Sun, C. A., Huang, G. T., . . . Duffy, S. W. (2002). Ultrasound screening and risk factors for death from hepatocellular carcinoma in a high risk group in Taiwan. International journal of cancer, 98(2), 257-261.

9. Gebo, K. A., Chander, G., Jenckes, M. W., Ghanem, K. G., Herlong, H. F., Torbenson, M. S., . . . Bass, E. B. (2002). Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review.

Hepatology, 36(5B), s84-s92.

10. Pedersen, J. H., Ashraf, H., Dirksen, A., Bach, K., Hansen, H., Toennesen,

P., . . . Seersholm, N. (2009). The Danish randomized lung cancer CT

screening trial--overall design and results of the prevalence round. Journal of Thoracic Oncology, 4(5), 608-614.

11. Feng, B., Zheng, M.-H., Zheng, Y.-F., Lu, A.-G., Li, J.-W., Wang, M.-L., . . . Zhu, Z.-G. (2005). Normal and modified urinary nucleosides represent novel biomarkers for colorectal cancer diagnosis and surgery monitoring. Journal of Gastroenterology and Hepatology, 20(12), 1913-1919.

12. Trevisani, F., D'Intino, P. E., Morselli-Labate, A. M., Mazzella, G., Accogli, E., Caraceni, P., . . . Bernardi, M. (2001). Serum α-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. Journal of hepatology, 34(4), 570-575.

13. Struck, W., Waszczuk-Jankowska, M., Kaliszan, R., & Markuszewski, M. J.

(2011). The state-of-the-art determination of urinary nucleosides using chromatographic techniques “hyphenated” with advanced bioinformatic methods. Analytical and Bioanalytical Chemistry, 401(7), 2039-2050.

14. Thompson, I. M., Pauler, D. K., Goodman, P. J., Tangen, C. M., Lucia, M. S., Parnes, H. L., . . . Coltman, C. A., Jr. (2004). Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

The New England Journal of Medicine, 350(22), 2239-2246.

15. Bjork, G. R., Ericson, J. U., Gustafsson, C. E., Hagervall, T. G., Jonsson, Y. H.,

& Wikstrom, P. M. (1987). Transfer RNA modification. Annual Review of Biochemistry, 56, 263-287.

16. Limbach, P. A., Crain, P. F., & McCloskey, J. A. (1994). Summary: the

modified nucleosides of RNA. Nucleic Acids Research, 22(12), 2183-2196.

17. Liebich, H. M., Muller-Hagedorn, S., Bacher, M., Scheel-Walter, H. G., Lu, X., Frickenschmidt, A., . . . Gerard, H. (2005). Age-dependence of urinary normal and modified nucleosides in childhood as determined by reversed-phase high-performance liquid chromatography. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 814(2), 275-283.

18. Lakings, D. B., Waalkes, T. P., Borek, E., Gehrke, C. W., Mrochek, J. E., Longmore, J., & Adamson, R. H. (1977). Composition, associated tissue methyltransferase activity, and catabolic end products of transfer RNA from carcinogen-induced hepatoma and normal monkey livers. Cancer Research,

37(1), 285-292.

19. Gehrke, C. W., Kuo, K. C., Davis, G. E., Suits, R. D., Waalkes, T. P., & Borek, E. (1978). Quantitative high-performance liquid chromatography of

nucleosides in biological materials. Journal of Chromatogry A, 150(2), 455-476.

20. Seidel, A., Brunner, S., Seidel, P., Fritz, G. I., & Herbarth, O. (2006). Modified nucleosides: an accurate tumour marker for clinical diagnosis of cancer, early detection and therapy control. British Journal of Cancer, 94(11), 1726-1733.

21. Itoh, K., Konno, T., Sasaki, T., Ishiwata, S., Ishida, N., & Misugaki, M. (1992).

Relationship of urinary pseudouridine and 1-methyladenosine to activity of leukemia and lymphoma. Clinica Chimica Acta, 206(3), 181-189.

22. Rasmuson, T., & Björk, G. R. (1995). Urinary excretion of pseudouridine and prognosis of patients with malignant lymphoma. Acta Oncologica, 34(1), 61-67.

23. Waalkes, T. P., Abeloff, M. D., Ettinger, D. S., Woo, K. B., Gehrke, C. W., Kuo, K. C., & Borek, E. (1982). Modified ribonucleosides as biological markers for patients with small cell carcinoma of the lung. European Journal of Cancer and Clinical Oncology, 18(12), 1267-1274.

24. Waalkes, T. P., Abeloff, M. D., Ettinger, D. S., Woo, K. B., Gehrke, C. W., Kuo, K. C., & Borek, E. (1982). Biological markers and small cell carcinoma of the lung: a clinical evaluation of urinary ribonucleosides. Cancer, 50(11), 2457-2464.

25. Tamura, S., Fujii, J., Nakano, T., Hada, T., & Higashino, K. (1986). Urinary pseudouridine as a tumor marker in patients with small cell lung cancer.

Clinica chimica Acta, 154(2), 125-132.

26. Sasco, A. J., Rey, F., Reynaud, C., Bobin, J. Y., Clavel, M., & Niveleau, A.

(1996). Breast cancer prognostic significance of some modified urinary nucleosides. Cancer Letter, 108(2), 157-162.

27. Zheng, Y.-F., Kong, H.-W., Xiong, J.-H., Lv, S., & Xu, G.-W. (2005). Clinical significance and prognostic value of urinary nucleosides in breast cancer patients. Clinical Biochemistry, 38(1), 24-30.

28. Cho, S.-H., Choi, M. H., Lee, W.-Y., & Chung, B. C. (2009). Evaluation of urinary nucleosides in breast cancer patients before and after tumor removal.

Clinical Biochemistry, 42(6), 540-543.

29. Hsu, W.-Y., Lin, W.-D., Tsai, Y., Lin, C.-T., Wang, H.-C., Jeng, L.-B., . . . Tsai, F.-J. (2011). Analysis of urinary nucleosides as potential tumor markers in human breast cancer by high performance liquid chromatography/electrospray ionization tandem mass spectrometry. Clinica Chimica Acta, 412(19-20), 1861-1866.

30. Lin, W., Mackenzie, J. W., McCoy, J. R., & Clark, I. (1983). Metabolism of tRNA in rats with aflatoxin B1-induced hepatomas. Cancer Biochemistry Biophysics, 7(1), 61-68.

31. Tamura, S., Amuro, Y., Nakano, T., Fujii, J., Moriwaki, Y., Yamamoto, T., . . . Higashino, K. (1986). Urinary excretion of pseudouridine in patients with hepatocellular carcinoma. Cancer, 57(8), 1571-1575.

32. Yang, J., Xu, G., ZHENG, Y., KONG, H., Pang, T., Lv, S., & Yang, Q. (2004).

Diagnosis of liver cancer using HPLC-based metabonomics avoiding false-positive result from hepatitis and hepatocirrhosis diseases. Journal of Chromatography B, 813(1-2), 59-65.

33. Chen, T.-z., & Huang, Z.-m. (2008). Significance of detection of urinary modifided nucleosides in diagnosis for hepatocellular carcinoma. Journal of Wenzhou Medical College, 38(5), 456-458.

34. Jeng, L.-B., Lo, W.-Y., Hsu, W.-Y., Lin, W.-D., Lin, C.-T., Lai, C.-C., & Tsai, F.-J. (2009). Analysis of urinary nucleosides as helper tumor markers in hepatocellular carcinoma diagnosis. Rapid Communications in Mass Spectrometry, 23(11), 1543-1549.

35. Hsu, W.-Y., Chen, W. T.-L., Lin, W.-D., Tsai, F.-J., Tsai, Y., Lin, C.-T., . . . Lai, C.-C. (2009). Analysis of urinary nucleosides as potential tumor markers in human colorectal cancer by high performance liquid

chromatography/electrospray ionization tandem mass spectrometry. Clinica Chimical Acta, 402(1-2), 31-37.

36. Valavanidis, A., Vlachogianni, T., & Fiotakis, C. (2009). 8-hydroxy-2' -deoxyguanosine (8-OHdG): A critical biomarker of oxidative stress and carcinogenesis. Journal of Environmental Science and Health Part C Environmental Carcinogenesis & Ecotoxicology Reviews, 27(2), 120-139.

37. Shibutani, S., Takeshita, M., & Grollman, A. P. (1991). Insertion of specific

bases during DNA synthesis past the oxidation-damaged base 8-oxodG.

Nature, 349(6308), 431-434.

38. Kamiya, H., Miura, K., Ishikawa, H., Inoue, H., Nishimura, S., & Ohtsuka, E.

(1992). c-Ha-ras containing 8-hydroxyguanine at codon 12 induces point mutations at the modified and adjacent positions. Cancer Research, 52(12), 3483-3485.

39. Ichinose, T., Yajima, Y., Nagashima, M., Takenoshita, S., Nagamachi, Y., &

Sagai, M. (1997). Lung carcinogenesis and formation of 8-hydroxy-deoxyguanosine in mice by diesel exhaust particles.

Carcinogenesis, 18(1), 185-192.

40. Chuma, M., Hige, S., Nakanishi, M., Ogawa, K., Natsuizaka, M., Yamamoto, Y., & Asaka, M. (2008). 8-Hydroxy-2'-deoxy-guanosine is a risk factor for development of hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Journal of Gastroenterology and Hepatology, 23(9),

1431-1436.

41. Mei, S., Yao, Q., Wu, C., & Xu, G. (2005). Determination of urinary 8-hydroxy-2'-deoxyguanosine by two approaches-capillary electrophoresis and GC/MS: an assay for in vivo oxidative DNA damage in cancer patients.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 827(1), 83-87.

42. Heiger, D. N. (1992). High performance capillary electrophoresis: an introduction. Hewlett Packard Company.

43. Landers, J. P. (1997). Handbook of Capillary Electrophoresis (2nd ed.). New York, USA: CRC Press.

44. Liu, X.-C. (2006). Boronic acids as ligands for affinity chromatography. Se Pu, 24(1), 73-80.

45. Zheng, Y.-F., Xu, G.-W., Liu, D.-Y., Xiong, J.-H., Zhang, P.-D., Zhang, C., . . . Lv, S. (2002). Study of urinary nucleosides as biological marker in cancer patients analyzed by micellar electrokinetic capillary chromatography.

Electrophoresis, 23(24), 4104-4109.

46. La, S., Cho, J., Kim, J.-H., & Kim, K.-R. (2003). Capillary electrophoretic profiling and pattern recognition analysis of urinary nucleosides from thyroid cancer patients. Analytica Chimica Acta, 486(2), 171-182.

47. Szymańska, E., Markuszewski, M. J., Bodzioch, K., & Kaliszan, R. (2007).

Development and validation of urinary nucleosides and creatinine assay by capillary electrophoresis with solid phase extraction. Journal of

Pharmaceutical and Biomedical Analysis, 44(5), 1118-1126.

48. Jiang, Y., & Ma, Y. (2009). A Fast Capillary Electrophoresis Method for Separation and Quantification of Modified Nucleosides in Urinary Samples.

Analytical Chemistry, 81(15), 6474-6480.

49. Wang, S., Zhao, X., Mao, Y., & Cheng, Y. (2007). Novel approach for developing urinary nucleosides profile by capillary electrophoresis-mass spectrometry. Journal of Chromatography A, 1147(2), 254-260.

50. Loftsson, T., & Duchene, D. (2007). Cyclodextrins and their pharmaceutical applications. International journal of pharmaceutics, 329(1), 1-11.

51. Lawson, C. L., van Montfort, R., Strokopytov, B., Rozeboom, H. J., Kalk, K.

H., de Vries, G. E., . . . Dijkstra, B. W. (1994). Nucleotide sequence and X-ray structure of cyclodextrin glycosyltransferase from Bacillus circulans strain 251 in a maltose-dependent crystal form. Journal of Molecular Biology, 236(2), 590-600.

52. Connors, K. A. (1997). The Stability of Cyclodextrin Complexes in Solution.

Chemical Reviews, 97(5), 1325-1358.

53. Davidson, C. D., Ali, N. F., Micsenyi, M. C., Stephney, G., Renault, S., Dobrenis, K., . . . Walkley, S. U. (2009). Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and

glycosphingolipid storage and disease progression. PLoS One, 4(9), e6951.

54. Gould, S., & Scott, R. C. (2005). 2-Hydroxypropyl-β-cyclodextrin (HP-β-CD):

a toxicology review. Food and Chemical Toxicology, 43(10), 1451-1459.

55. Ding, X., Li, Y., Song, B., Zhao, S., & Wang, Z. (2011). C1-1-Dairy Science &

technology. Dairy Science & Technology, 91, 759-770.

56. Hoffman, J. L. (1970). Chromatography of nucleic acid components on cyclodextrin gels. Analytical Biochemistry, 33(2), 209-217.

57. Madhusudanan, K. P., Katti, S. B., & Dwivedi, A. K. (1998). Non-covalent complexes of nucleosides and nucleobases with β-cyclodextrin: a study by fast atom bombardment mass spectrometry and collision-induced dissociation.

Journal of Mass Spectrometry, 33(10), 1017-1022.

58. Tadey, T., & Purdy, W. C. (1994). Capillary electrophoretic separation of nucleotide isomers via complexation with cyclodextrin and borate. Journal of Chromatography B: Biomedical Sciences and Applications, 657(2), 365-372.

59. ZHOU, W.-f., LI, X.-j., ZHANG, Y.-p., & YUAN, Z.-b. (2003). High Performance Capillary Electrophoretic Separation of Nucleotides via Complexation with β - Cyclodextrin and Borate. Journal of Instrumental Analysis, 22(3), 7-10.

60. Grob, M. K., O’Brien, K., Chu, J. J., & Chen, D. D. Y. (2003). Optimization of cellular nucleotide extraction and sample preparation for nucleotide pool analyses using capillary electrophoresis. Journal of Chromatography B, 788(1), 103-111.

61. Schlimme, E., Boos, K. S., Hagemeier, E., Kemper, K., Meyer, U., Hobler, H., . . . Weise, M. (1986). Direct clean-up and analysis of ribonucleosides in physiological fluids. Journal of Chromatography, 378(2), 349-360.

62. Boos, K. S., Wilmers, B., Schlimme, E., & Sauerbrey, R. (1988). On-line sample processing and analysis of diol compounds in biological fluids.

Journal of Chromatography, 456(1), 93-104.

63. Liotta, E., Gottardo, R., Bonizzato, L., Pascali, J. P., Bertaso, A., & Tagliaro, F.

(2009). Rapid and direct determination of creatinine in urine using capillary zone electrophoresis. Clinica Chimica Acta, 409(1–2), 52-55.

64. Muñoz, J. A., López-Mesas, M., & Valiente, M. (2010). Development and validation of a simple determination of urine metabolites (oxalate, citrate, uric acid and creatinine) by capillary zone electrophoresis. Talanta, 81(1-2), 392-397.

65. Gehrke, C. W., Kuo, K. C., Waalkes, T. P., & Borek, E. (1979). Patterns of urinary excretion of modified nucleosides. Cancer Research., 39(4), 1150-1153.

在文檔中以毛細管電泳偵測尿尿液中核苷作為癌症生物標記之研究 (頁 83-90)

第六六章 參參考文獻

第六六章參參考文獻